At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed Nov 10, 2026 at 16:02 ET
Kura Oncology reported Q3 2026 results with KOMZIFTI net product revenue of $13.9M, up 53% sequentially, and a net loss of $70.2M ($0.78 per share) versus consensus EPS of -$0.81. The company also announced FDA alignment on a darlifarnib registrational study and a $300M Oberland Capital financing facility.
- KOMZIFTI net product revenue $13.9M in Q3 2026, up 53% from Q2 2026
- Net loss $70.2M ($0.78 per share) vs consensus EPS -$0.81
- Total revenue $22.8M (product $13.9M + collaboration $8.9M)
- Cash and investments $492.1M as of Sep 30, 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access